Published August, 2012
By Donald Armstrong
Publisher: Springer (Humana Press Inc.)
Series: Methods in Molecular Biology
Rating:
Availability: Available

In Lipidomics: Methods and Protocols, an international panel of experts present a wide variety of reviewed as well as unpublished data on isolation techniques, structural analysis, lipid rafts, lipid trafficking and profiling, biomarkers, lipid peroxidation, biostatistics applied to lipids, software tools, and bioinformatics.

---

Published August, 2012
By Donald Armstrong
Publisher: Springer (Humana Press Inc.)
Series: Methods in Molecular Biology
Rating:
Availability: Available

In Lipidomics: Methods and Protocols, an international panel of experts present a wide variety of reviewed as well as unpublished data on isolation techniques, structural analysis, lipid rafts, lipid trafficking and profiling, biomarkers, lipid peroxidation, biostatistics applied to lipids, software tools, and bioinformatics.

---

Published August, 2012
By Vadim Astakhov
Publisher: Springer (Humana Press Inc.)
Series: Methods in Molecular Biology
Rating:
Availability: Available

In past decades, the area of bioinformatics has proved to be both dynamic and vital, producing a wide spectrum of novel approaches and assuming an increasingly important role in modern bio-technological development.

---

Published August, 2012
By Blake C. Meyers and Pamela J. Green
Publisher: Springer (Humana Press Inc.)
Series: Methods in Molecular Biology
Rating:
Availability: Available

MicroRNAs constitute a particularly important class of small RNAs given their abundance, broad phylogenetic conservation and strong regulatory effects, with plant miRNAs uniquely divulging their ancient evolutionary origins and their strong post-transcriptional regulatory effects.

---

Published August, 2012
By Jun Zhou
Publisher: Springer (Humana Press Inc.)
Series: Methods in Molecular Biology
Rating:
Availability: Available

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix 1 Multidrug Resistance in Cancer . Baguley 2 Multidrug Resistance in Oncology and Beyond: From Imaging of Drug Efflux Pumps to Cellular Drug Targets .

---

Published August, 2012
By John D. Lambris and V. Michael Holers
Publisher: Springer (Humana Press Inc.)
Series: Contemporary Immunology
Rating:
Availability: Available

A team of expert investigators and clinical researchers comprehensively review complement's basic biology, its role in disease, methods to measure its activity, and strategies for its inhibition in patients.

---

Published August, 2012
By Beverly A. Teicher and Paul A. Andrews
Publisher: Springer (Humana Press Inc.)
Series: Cancer Drug Discovery and Development
Rating:
Availability: Available

Since the earliest widely used in vivo drug screening models were the murine L 1210 and P388 leukemias, the community came to assume that these murine tumor models were appropriate to the discovery of "antileukemia" agents, but that other tumor models would be needed to discover drugs active against solid tumors.

---

Published August, 2012
By R. Alan B. Ezekowitz and Jules A. Hoffmann
Publisher: Springer (Humana Press Inc.)
Series: Infectious Disease
Rating:
Availability: Available

The concept of innate immunity refers to the first-line host defense that serves to limit infection in the early hours after exposure to microorganisms.

---

Published August, 2012
By William S. Weintraub
Publisher: Springer (Humana Press Inc.)
Series: Contemporary Cardiology
Rating:
Availability: Available

An illuminating and timely synthesis of methodological and clinical studies showing how medical costs can be established, how the value of clinical outcomes can be assessed, and how difficult choices can be rationally made.

---

Published August, 2012
By Ronald M. Bukowski and James H. Finke
Publisher: Springer (Humana Press Inc.)
Series: Current Clinical Oncology
Rating: 1.00
Availability: Available

Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction.

---